Related Experiment Video
Updated: Nov 1, 2025
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Glycoengineering artificial receptors for microglia to phagocytose Aβ aggregates
Dongqin Yu1,2, Chun Liu1,2, Haochen Zhang1,2
1Laboratory of Chemical Biology, State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun Jilin 130022 P. R. China xqu@ciac.ac.cn.
Abstract:
Oligomeric and fibrillar amyloid-β (Aβ) are principally internalized via receptor-mediated endocytosis (RME) by microglia, the main scavenger of Aβ in the brain. Nevertheless, the inflammatory cascade will be evoked after vast Aβ aggregate binding to pattern recognition receptors on the cell membrane, which then significantly decreases the expression of these receptors and further deteriorate Aβ deposition. This vicious circle will weaken the ability of microglia for Aβ elimination. Herein, a combination of metabolic glycoengineering and self-triggered click chemistry is utilized to engineer microglial membranes with ThS as artificial Aβ receptors to promote microglia to phagocytose Aβ aggregates. Additionally, to circumvent the undesirable immune response during the process of the bioorthogonal chemistry reaction and Aβ-microglial interaction, Mn-porphyrin metal-organic frameworks (Mn-MOFs) with superoxide dismutase (SOD) and catalase (CAT) mimic activity are employed to carry N-azidoacetylmannosamine (AcManNAz) and eradicate over-expressed reactive oxygen species (ROSs). The artificial Aβ receptors independent of a signal pathway involved in immunomodulation as well as Mn-MOFs with antioxidant properties can synergistically promote the phagocytosis and clearance of Aβ with significantly enhanced activity and negligible adverse effects. The present study will not only provide valuable insight into the rational design of the microglial surface engineering strategy via bioorthogonal chemistry, but also hold great potential for other disease intervention associated with receptor starvation.
Insights
Researchers engineered microglial cells to enhance amyloid-beta (Aβ) clearance using artificial receptors and antioxidants. This approach boosts microglial phagocytosis of Aβ aggregates, offering a novel strategy for neurodegenerative diseases.
Area of Science:
- Biomaterials Science
- Neuroscience
- Immunology
Background:
- Microglia are crucial for clearing amyloid-beta (Aβ) aggregates in the brain.
- Receptor-mediated endocytosis (RME) is the primary Aβ uptake mechanism by microglia.
- Aβ binding triggers inflammatory responses, downregulating microglial Aβ receptors and impairing clearance, creating a detrimental cycle.
Purpose of the Study:
- To engineer microglial membranes with artificial Aβ receptors to enhance Aβ phagocytosis.
- To mitigate immune responses and oxidative stress during Aβ clearance.
- To develop a novel strategy for improving microglial Aβ clearance in neurodegenerative diseases.
Main Methods:
- Metabolic glycoengineering and click chemistry were used to create ThS-functionalized artificial Aβ receptors on microglial surfaces.
- Manganese-porphyrin metal-organic frameworks (Mn-MOFs) with superoxide dismutase (SOD) and catalase (CAT) mimic activity were employed.
- Mn-MOFs carried N-azidoacetylmannosamine (AcManNAz) to neutralize reactive oxygen species (ROS).
Main Results:
- Engineered microglial cells demonstrated enhanced phagocytosis of Aβ aggregates.
- The artificial receptors bypassed immunomodulatory pathways, reducing adverse immune reactions.
- Mn-MOFs effectively scavenged ROS, protecting microglia and improving Aβ clearance efficiency.
- The combined strategy significantly enhanced Aβ clearance with minimal side effects.
Conclusions:
- Microglial surface engineering via bioorthogonal chemistry offers a promising approach to boost Aβ clearance.
- Artificial Aβ receptors and antioxidant Mn-MOFs synergistically enhance microglial phagocytic capacity.
- This strategy holds potential for treating diseases characterized by impaired receptor function and Aβ deposition.
